VEEV — Veeva Systems Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $301.53
- YTD price return
- +35.08%
- YTD total return
- +35.08%
- Next earnings
- Nov 19, 2026
- Market cap
- 48.8B
- Enterprise value
- 47.2B
- Shares outstanding
- 161.9M
- 52W low
- $148.05
- 52W high
- $325.99
- From 52W high
- -7.50%
- From 52W low
- +103.67%
- 52W range
- 86%$148–$326
- Beta
- 0.92
Volume
- Rel volume
- 0.51×
- 30D volume
- 1.4M
- 30D $ vol
- 441.1M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$6.2M
- Insider net 1Y
- −$16.8M
Form 4 transactions by trade date, as filed; latest on file 2026-10-14.
Fundamentals
- Sales (ttm)
- 3.5B
- Sales/share
- $21.36
- EPS (ttm)
- $6.11
- FCF (ttm)
- 1.6B
- FCF/share
- $10.12
- Book value/share
- $45.90
- Net margin
- 29.34%
- ROE
- 13.66%
- ROA
- 11.20%
- Current ratio
- 5.46
Growth (CAGR, ttm) · 10Y
- Sales
- +16.52%+15.70%+15.76%+22.03%
- Net income
- +25.31%+23.39%+19.06%+34.21%
- FCF
- +23.41%+19.72%+16.93%+28.43%
- Shares
- -1.22%-0.28%-0.11%+0.96%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +25.54%+22.59%+18.46%+32.38%
- Sales/share
- +17.96%+16.03%+15.89%+20.87%
- FCF/share
- +24.94%+20.06%+17.06%+27.21%
- Book value/share
- +13.34%+21.75%+23.32%+28.16%
- Price
- +3.37%+21.95%-1.04%+22.49%
- Total return
- +3.37%+21.95%-1.04%+22.49%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 49.3×
- P/OI (ttm)
- 47.2×
- Fwd P/E
- 29.4×
- P/S (ttm)
- 14.1×
- P/B (mrq)
- 6.6×
- P/FCF (ttm)
- 29.8×
- EV/EBITDA (fy)
- 43.9×
- EV/Sales (ttm)
- 13.6×
- FCF yield (ttm)
- 3.36%
- Buyback yield (realized, 1y)
- 1.22%
- Shareholder yield (realized, 1y)
- 1.22%
- Buyback yield (cash, ttm)
- 1.32%
- Shareholder yield (cash, ttm)
- 1.32%
Vs own 10Y history
- P/E
- 10th
- P/OI
- 10th
- P/S
- 38th
- P/B
- 17th
- P/FCF
- 12th
Bar = where today’s multiple sits in VEEV’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-13#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +19.4%10Y CAGR +27.8%YoY +40.4%EPS (diluted)
5Y CAGR +18.2%10Y CAGR +30.5%YoY +39.5%Free cash flow
5Y CAGR +20.6%10Y CAGR +37.2%YoY −0.6%TTM: operating cash flow $1.7B, capex −$26.7M
Q2 2027: operating cash flow $238.7M, capex −$8M
Shares (diluted)
5Y +3.9%10Y +15.2%YoY −1.6%Net income
5Y CAGR +19.1%10Y CAGR +32.5%YoY +36.5%About Veeva Systems#
Data provided bySource: Twelve DataVeeva Systems Inc. is a cloud software company that provides industry-specific solutions for the global life sciences sector. Veeva Systems Inc. offers applications, data, and consulting services designed to support pharmaceutical, biotechnology, and medical device companies across research and development, quality, and commercial operations. Its product portfolio includes platforms for clinical, regulatory, quality, and field activities, along with customer relationship management, content management, analytics, and data services tailored to life sciences workflows. The company also delivers cloud-based tools that help organizations manage complex processes from drug development through commercialization. Veeva Systems Inc. plays a central role in the life sciences technology market by combining software and data in a specialized industry cloud built for highly regulated environments. Founded in 2007 and headquartered in Pleasanton, California, the company focuses on serving customers that need compliant, scalable digital systems for critical business functions.
Pleasanton, CA·7,928 employees·Health Information Services·veeva.com·As of Oct 28, 2026
Recent filings#
- Nov 68-K · Results of operations
- Oct 2Insider sale · Rizzo Daniel J (EVP, Sales, Consulting, & Svcs) sold 4,841 Class A shares for $1.3M at $276.21–$276.53
- Sep 9Insider sale · Hung Priscilla (Director) sold 750 Class A shares for $196K at $261.04
- Aug 26Earnings · Earnings release — EPS $1.68 vs $1.62 est. (+3.7%); revenue $928.0M (+18% y/y) 15.2%
ETFs holding VEEV#
34 of the 193 ETFs ChartRow carries live hold VEEV. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| VHT | Vanguard Health Care ETF | 0.6% |
| COWZ | Pacer US Cash Cows 100 ETF | 0.6% |
| VOT | Vanguard Mid-Cap Growth ETF | 0.6% |
| XLV | Health Care Select Sector SPDR Fund | 0.5% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.3% |
| VO | Vanguard Mid-Cap ETF | 0.3% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
| IWR | iShares Russell Midcap ETF | 0.2% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +23.75% | +1.14% |
| JNJ | Johnson & Johnson | +14.94% | +0.79% |
| ABBV | AbbVie Inc. | +7.53% | +0.20% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +7.86% | +0.58% |
| MRK | Merck & Co. Inc. | +4.07% | +0.55% |
| NVS | Novartis AG | +12.70% | +0.16% |
| TMO | Thermo Fisher Scientific Inc. | +5.61% | +0.11% |
| AMGN | Amgen Inc. | +12.80% | -0.30% |
